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treated patients, the generic SF-36 and DFS speciﬁc for patients
with foot ulcers. Six other instruments were well validated and
widely used, but their responsiveness was not documented and
their sensitivity to change in RCTs was not consistent across the
trials. CONCLUSIONS: Though several instruments have been
identiﬁed, most of the them are speciﬁc for a subtype of diabetic
population (type 1 or type 2, insulin-treated, patients with com-
plications) and do not meet all criteria in regard to their psy-
chometric properties. Further research is warranted to assess the
sensitivity to change of diabetes speciﬁc patient reported out-
comes instruments.
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OBJECTIVE: Assessment of diabetic patients’ Willingness To
Pay (WTP) for inhaled insulin in relation to injected insulin.
METHODS: A questionnaire concerning preference and WTP
for inhaled insulin was completed by 157 patients (age range,
20–65 years) in Sweden. Type 1 diabetic patients were receiving
treatment with insulin (n = 40) and Type 2 patients were receiv-
ing treatment with either insulin as single therapy (n = 21), a
combination therapy with insulin and anti-diabetic drugs (n =
46), or an oral anti-diabetic treatment with at least 2 oral drugs
(n = 50). Patients were asked to assess their WTP for inhaled
insulin by choosing from eight comparisons, at different prices.
A Conditional Logit model was used to estimate the utility as a
function of treatment and price. The WTP measure were the
incremental price patients were willing to pay for inhaled insulin
compared to injected insulin. RESULTS: Patients were willing to
pay an additional 400SEK [50 US dollars] per month (on
average) for inhaled insulin in comparison to injected insulin.
Type 1 patient reported a lower marginal WTP than Type 2
patients. Type 1 patients were willing to pay an additional 219
SEK. Type 2 patients on insulin as single therapy, or on a com-
bination therapy with insulin and anti-diabetic drugs, or treated
with an oral anti-diabetic treatment with at least 2 oral drugs
were willing to pay additionally 375SEK, 381SEK, 667SEK,
respectively. At equal prices (500SEK) a total of 129 patients
(85%) preferred insulin inhalation. At a large price difference,
(300SEK vs 1400SEK), only 16% preferred inhalations.
However, as many as 27 percent of patients on oral antidiabetic
drug treatment still preferred inhaled insulin. CONCLUSION:
In comparison to injected insulin 85% of patients preferred
inhaled insulin at equal prices and patients are on average willing
to pay 400SEK per month.
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OBJECTIVES: To assess the beneﬁcial and harmful effects of
hepatitis B active immunisation (vaccines) and passive immuni-
sation (immunoglobulins) in newborns of HBsAg-positive
mothers. METHODS: By using the Cochrane Collaboration
methodology we reviewed all randomised trials to assess the ben-
eﬁcial and harmful effects of hepatitis B active immunisation
(vaccines) and passive immunisation (immunoglobulins) for
newborns of positive hepatitis B surface antigen (HBsAg)
mothers. Trials were identiﬁed through the trial registers of 
The Cochrane Hepato-Biliary Group, The Cochrane Neonatal
Group, The Cochrane Library, MEDLINE, EMBASE, authors of
trials, and industry until February 2004. RESULTS: Compared
with placebo/no intervention, hepatitis B immunoglobulins
(HBIG) signiﬁcantly reduced hepatitis B occurrences (RR 0.50,
95% CI 0.41 to 0.60). Compared with vaccination alone, vac-
cination plus HBIG signiﬁcantly reduced hepatitis B occurrences
(RR 0.54, 95% CI 0.41 to 0.73). HBIG signiﬁcantly reduced
hepatitis B occurrences if administered within 12 hours of birth,
but not within 24 or 48 hours of birth. No signiﬁcant difference
on hepatitis B occurrence was found between recombinant
vaccine (RV) or plasma-derived vaccine (PDV) (RR 1.00, 95%
CI 0.71 to 1.42). No signiﬁcant differences on hepatitis B occur-
rences were found between high-dose PDV and low-dose PDV
(RR 0.97, 95% CI 0.55 to 1.68) or high-dose RV and low-dose
RV (RR 0.78, 95% CI 0.31 to 1.94). Hepatitis B vaccines and
HBIG seem generally safe, but few trials reported on adverse
events. In general, methodological quality did not signiﬁcantly
inﬂuence the results. CONCLUSIONS: Hepatitis B vaccination
and HBIG within 12 hours of birth signiﬁcantly reduces hepati-
tis B occurrences in infants of HBsAg-positive mothers.
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OBJECTIVES: To examine dose-response relation of interferon-
a in patients with HBeAg positive chronic hepatitis B (CHB) and
quantify the effect size of treatment in different regimens.
METHODS: We searched Medline, SCI-expanded, Current
Content Connect, Cochrane Library, and Chinese Biomedical
Database to September 2005, and screened references of eligible
studies. Randomized trials comparing interferon-a with non-
antiviral interventions (placebo/no treatment/standard care) in
patients with HBeAg-positive CHB were included. Heterogene-
ity was examined by the Q statistics and Galbraith plots. 
Meta-regression was used to analyze the relation of study char-
acteristics to treatment outcomes. Fixed and random effect meta-
analysis were used to pooled virological and serological
response. When results differed in two models, random effect
model was reported. RESULTS: Thirty-two trials were included
(n = 2164). Dose of interferon-ranged from 1–10MU, treatment
duration ranged from 4–24 weeks, and length of follow-up
varied from 12–130 weeks. Loss of HBeAg was responsive to
dose (coefﬁcient = 0.156, 95% CI = 0.028–0.28) and duration
(coefﬁcient = 0.076, 95%CI = 0.0048–0.15), while other out-
comes were not. Stratiﬁed analyses showed that high-dose (≥5
MU) and regular duration (16–24 weeks) could effectively clear
HBeAg (OR = 3.28, 95% CI = 2.31–4.66; OR = 3.28, 95% CI
= 2.16–5.00), and clear HBV DNA (OR = 2.80, 95% CI =
2.03–3.86; OR = 2.58, 95% CI = 1.62–4.12). HBeAg serocon-
version could be seen in all-dose groups (OR = 2.02, 95% CI =
1.37–2.97). The number-needed-to-treat for loss of HBeAg was
four in high-dose and nine in low-dose treatment. Speciﬁcally, a
high-dose and regular-duration of interferon-Á was associated
with signiﬁcantly higher loss of HBeAg in Chinese patients (OR
= 2.99, 95% CI = 1.53–5.87; OR = 2.56, 95% CI = 1.23–5.33),
which otherwise was not effective in clearing HBV DNA. CON-
